Xintian Pharma(SZ:002873) Xin Lang Cai Jing·2025-08-26 11:49Group 1 - The company held an investor relations event with 10 institutions, including Morgan Stanley Fund and Caitong Fund, on August 26, 2025, in Shanghai [1] - The company is advancing multiple research pipelines in important therapeutic areas, including oncology, cardiovascular, gynecology, and urology, with significant progress in clinical trials and drug development [2] - The company has made substantial investments in Huilun Pharmaceutical, focusing on major diseases and critical care, with nearly 20 innovative drug research pipelines expected to enter clinical phases by the end of the year [3] Group 2 - The company has not been affected by centralized procurement due to its unique patented products and is increasing investment in the OTC market while enhancing brand building [4] - The company experienced a decline in operating performance in the first half of 2025 due to rising raw material prices and changes in the pharmaceutical industry, but anticipates a return to stable growth as raw material prices decrease [4] - The company emphasizes the importance of traditional Chinese medicine innovation in the pharmaceutical industry and has established a comprehensive R&D platform to ensure balanced strategic development and shareholder returns [5]